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) and dose ratio. RESULTS: A total of 2322 EPO and 4353 DARB formed the study population. EPO patients were older (57.7 vs. 55.7 years; p < 0.0001) and a lower proportion were women (65% vs. 69%; p = 0.0002), compared to DARB patients. Mean ESA treatment duration was slightly longer in the EPO group (59 vs. 55 days; p = 0.0001). The mean cumulative dose (SD) was 312,723 (255,432) Units for EPO and 1174 (833) mcg for DARB, resulting in a dose ratio of 266:1 (Units EPO : mcg DARB). Based on these doses, WAC-based ESA cost was 28% less for EPO than for DARB (EPO $3915; DARB $5434; p < 0.0001). A sensitivity analysis using January 2008 average sales price +6% also indicated lower cost for EPO (EPO $2803; DARB $3396; p < .0001). This finding was also maintained after adjusting for age, gender, treatment duration, payer type, type of malignancies, cancer treatments, and severity indicators, (adjusted cost difference: $1788, p < 0.0001). CONCLUSION: This observational study of 6675 cancer patients reported a dose ratio of 266:1 which resulted in a 28% lower drug cost in the EPO group compared to the DARB group. These findings provide greater understanding of current real-world ESA utilization in the managed care setting. (without organized screening) we found a decreasing tendency in these two age-groups: 15-19 years: -0.06 percent point decrease (non-significant), 20-24 years: -6.28 percent point decrease (p < 0.01). CONCLUSION: We found that coverage of women aged 20-24 being out of the scope of the organized cervical cancer screening programme is higher (61.2 %) than the average of target age group of 25-64 years (52.65). Despite of this finding, the coverage of women 15-19 and 20-24 showed a decreasing tendency following the introduction of organized screening programme. Cancer continues to be a leading cause of death, but the last few decades have seen many changes in the diagnosis and treatment of the disease. In this study, we estimate the economic value of gains in cancer survival over the last 20 years, separate these gains into the portions due to improvements in treatment and detection, and determine the extent to which the economic value of gains in cancer survival have been divided between patients and firms. METHODS: Using methodology developed by Philipson and Jena (2005), we estimated the economic value of gains in cancer survival between 1990 and 2000. We then used estimates from the literature to calculate expenditures on cancer treatment, thereby allowing us to determine how the social value of gains in cancer treatment has been divided between patients and firms. RESULTS: The value of survival gains for all cancers combined was worth roughly $28,000-$30,000 per cancer patient, and most (78-88%) of this gain has been driven by improvements in treatment. For all cancers combined, improvements in cancer survival between 1990 and 2000 had a social value of roughly $1.6-$1.9 trillion, and health care providers were able to appropriate 6-19% of this total, with the rest accruing to patients. CONCLUSION: The social value of recent gains in cancer survival is very large. Most of this gain has been driven by improvements in cancer treatment, and has been appropriated by patients, not health care providers. To describe how decision making in the Cancer Subcommittee of the Ontario Committee to Evaluate Drugs (responsible for deciding which novel and costly cancer drugs will be funded in Ontario) is evolving along three scientific paradigms. METHODS: We describe how these paradigms shape both criteria and process of decision making. We also systematically reviewed meeting transcripts to analyze decisions made in 2006. RESULTS: Evidence Based Medicine (I) is part of decision making through rigorous evidence reviews and the implicit rule that drugs must pass the threshold of effectiveness to be funded. Although drugs must pass one evidence threshold to be licenced in Canada, higher standards are required for reimbursement (e.g. phase III controlled trial data, peer reviewed publication). Health economic criteria (II) are assuming greater weight in decision making, as the review process is standardized, committee members become more economically literate, and a cancer pharmacoeconomics unit is established. The process of decision making (versus decision criteria) is evolving using the ethical foundations of Accountability for Reasonableness (III), important tenets of which are transparency, accountability, and stakeholder involvement in the decision process. Review of the 2006 decisions showed that 16 of 37 drugs were funded (43%). Among negative funding decisions 86% were characterized by inadequate evidence (main reason in 43%), 71% were characterized by cost effectiveness concerns (main reason in 15% ), and 5% by ethical concerns (main reason in 5%). Forty-eight percent of decisions were multifactorial. CONCLUSION: Each paradigm used to make cancer drug funding decisions comes from a distinct intellectual tradition. Most decisions in 2006 were based on more than one paradigm. We believe that optimal decision making for cancer drugs involves integrating concepts from all traditions, involving both distinct decision criteria and decision processes. Integration requires judicious tradeoffs between both efficiency and equity, and evidence quality and efficiency/equity.
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